Erratum to: Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee

Karel Pavelka · Philippe Coste · Pál Géher ·
Gerhard Krejci

Published online: 30 April 2010
© Clinical Rheumatology 2010

Erratum to: Clin Rheumatol DOI 10.1007/s10067-010-1384-8

This article contains three errors in the Discussion:

“Maheu et al. treated 164 patients with osteoarthritis of the knee (114) and hip (50) for 6 months and followed-up for an additional 2 months either ASU 300 or 600 mg (85 patients) or placebo (79 patients).”

should read:

“Maheu et al. treated 164 patients with osteoarthritis of the knee (114) and hip (50) for 6 months and followed-up

for an additional 2 months either ASU 300 mg (85 patients) or placebo (79 patients).”

“Appelboom et al. treated 260 patients with knee osteoarthritis 300 or 600 mg daily ASU for 3 months. The primary endpoint (NSAIDs and analgesics intake) between days 30 and 90 decreased by more than 50% in 71% of the patients compared with 36% of the patients receiving placebo.”

should read:

“Appelboom et al. treated 260 patients with knee osteoarthritis 300 or 600 mg daily ASU for 3 months. The primary endpoint (NSAIDs and analgesics intake) between days 30 and 90 decreased by more than 50% in 71% of the patients receiving ASU compared with 36% of the patients receiving placebo.”

“Meta-analysis of 19 studies over 1,328 diacerein—another member of the SYSADOA group—treated and 1,309 patients treated with a comparator showed that diacerein was significantly superior to placebo and equal efficacious to NSAIDs with a 3 months carry-over effects with excellent tolerability [37].”

should read:

“Meta-analysis of 19 studies over 1,328 diacerein—another member of the SYSADOA group—treated and 1,309 patients treated with a comparator showed that diacerein was significantly superior to placebo and equal efficacious to NSAIDs with a 3 months carry-over effects with reasonable tolerability [37].”

The online version of the original article can be found under <http://dx.doi.org/10.1007/s10067-010-1384-8>.

K. Pavelka
Institute of Rheumatology, Charles University Prague,
Prague, Czech Republic

P. Coste (✉)
Laboratoire Expanscience,
Courbevoie, France
e-mail: pcoste@expanscience.com

P. Géher
Hospital of St. John's of God,
Budapest, Hungary

G. Krejci (✉)
Clinical Investigations Ltd, Imre u. 4,
1093 Budapest, Hungary
e-mail: g.krejci@clinical-investigations.com